Welcome, this website is intended for all international healthcare professionals in uro-oncology. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

News Items

  • ESMO2014 update on Abiraterone

    Abiraterone and prednisone in men with CRPC prior to docetaxel earlier showed improved progression-free survival but follow up was too short to meet the co-primary endpoint of the COU-AA302 study: overall survival.

  • Cabozantinib fails to significantly prolong survival in men with metastatic Castration-Resistant Prostate Cancer

    Cabozantinib (XL184) is an oral tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. Although other VEGFR-targeting agents have failed in prostate cancer, expectations amongst oncologists were high that cabozantinib that also targets c-Met, critical in bone metastasis, would be a winning horse in metastatic castrate-resistant prostate cancer.